NCT04223869

Brief Summary

The objective of this study is to 1) identification of the impact of IL-34 on the pathogenesis of periodontal disease and determine whether any relationship among the existing levels of Gingival crevicular fluid (GCF) Interleukin 34( IL-34 )and GCF Receptor activator of nuclear factor -kB ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio, as a mediator of bone resorption 2) analysis of the impact of non-surgical periodontal treatment on GCF IL-34 levels in patients with chronic periodontitis (CP) and aggressive periodontitis (AgP) and 3) to correlate between biochemical markers and clinical recordings

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jan 2015

Typical duration for not_applicable

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2015

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2016

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

January 8, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 10, 2020

Completed
Last Updated

January 10, 2020

Status Verified

January 1, 2020

Enrollment Period

1.1 years

First QC Date

January 8, 2020

Last Update Submit

January 8, 2020

Conditions

Keywords

PeriodontitisInterleukin 34RANKLOPGgingival crevicular fluid

Outcome Measures

Primary Outcomes (1)

  • gingival crevicular fluid IL-34 level

    gingival crevicular fluid IL-34 levels change from baseline to at 6th week

    6th week

Secondary Outcomes (6)

  • Gingival crevicular fluid RANKL level

    6th week

  • Gingival crevicular fluid OPG level

    6th week

  • Plaque index

    6th week

  • Gingival index

    6th week

  • bleeding on probing

    6th week

  • +1 more secondary outcomes

Study Arms (3)

periodontally healthy group

NO INTERVENTION

Control

Chronic Periodontitis

ACTIVE COMPARATOR

non-surgical periodontal treatment was performed

Other: non-surgical periodontal treatment

Aggressive Periodontitis

ACTIVE COMPARATOR

non-surgical periodontal treatment was performed

Other: non-surgical periodontal treatment

Interventions

scaling and root planing were performed

Aggressive PeriodontitisChronic Periodontitis

Eligibility Criteria

Age20 Years - 55 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • CP group included 20 patients, ≥ 35 years of age, and this category was displayed as a minimum of six teeth available clinical attachment loss (AL) and pocket probing depth (PPD) ≥ 5mm. These teeth exhibited positive bleeding on probing (BOP) across a minumum 2 separate quadrants and bone loss affecting \>30 % of available teeth on clinical and radiographic inspection. The gingival index (GI) score for indications of inflammation (red color and edema of the gingival margin) was \>1 for the CP group.
  • AgP group included 20 patients, \<35 years of age, and cases showed PPD≥ 5mm with at least six teeth and radiographic evidence of alveolar bone loss. At least three of these six teeth with PPD ≥ 5 mm were not molars or incisors. These patients showed severe periodontal tissue devastation and decrease of periodontal support conflicting with age and plaque levels.
  • Control group included 20 participants and they presented PPD ≤ 3mm, GI=0 (nonavailable of clinical inflammation), absence of alveolar bone loss (e.g., distance between the cemento-enamel junction and the bone crest was \<3mm in\> 95% of proximal tooth sites).
  • All participants had minimum 20 teeth and their overall systematic health

You may not qualify if:

  • lactation
  • pregnancy
  • current and ex-smoking habits
  • undergone nonsurgical periodontal therapy and prescription of antibiotics or non-steroidal anti-inflammatory medication within the previous 6 months or surgical periodontal treatment within the preceding year
  • postmenopause
  • systemic conditions such as; diabetes mellitus, cancer, cardiovascular and respiratory diseases, rheumatoid arthritis, osteoporosis, or immunologic disorders, that might cause progress of periodontal disease.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Chronic PeriodontitisAggressive PeriodontitisPeriodontitis

Condition Hierarchy (Ancestors)

Periodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Umut Ballı, PhD, DDS

    Bülent Ecevit University Faculty of Dentistry

    PRINCIPAL INVESTIGATOR
  • Figen Öngöz Dede, PhD, DDS

    Ordu University

    PRINCIPAL INVESTIGATOR
  • Şeyma Bozkurt Doğan, PhD, DDS

    Ankara Yildirim Beyazıt University

    STUDY CHAIR
  • Erdim Sertoğlu, PhD, DDS

    Ankara Sağlık Bilimleri University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 8, 2020

First Posted

January 10, 2020

Study Start

January 1, 2015

Primary Completion

February 1, 2016

Study Completion

May 1, 2017

Last Updated

January 10, 2020

Record last verified: 2020-01